XNK Therapeutics receives US orphan drug status for NK cell-based immunotherapy in multiple myeloma
November 4, 2020 XNK Therapeutics AB (“XNK”) today announced it has received Orphan Drug Designation (ODD) from the U.S. Food and Drug Administration (FDA) for its leading investigational drug candidate in the treatment of multiple myeloma (MM).Receiving ODD status from the FDA for the treatment of multiple myeloma is a critical next step for the development of XNK’s leading investigational drug candidate. XNK has already received ODD status in the EU. “Obtaining an ODD by the FDA is a significant milestone for XNK and our goal of taking the present drug candidate to the next level,”